Work

Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype ( EGFR wt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3027

Authors: David Ross Camidge, Shun Lu, Jonathan W. Goldman, Hidehito Horinouchi, Christine Ratajczak, Shilpen Patel, Xizhi (Adam) Luo, Yan Sun, Shanmugapriya Ganesan, Hossein M. Foroushani, Yilin Xu, Qu Zhang, Tony Navas, Peter Ansell, Jair Bar

Institutions: University of Colorado Cancer Center, Shanghai Jiao Tong University, University of California, Los Angeles, National Cancer Center Hospital, AbbVie (United States), Tel Aviv University, Sheba Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AbbVie

OpenAlex ID: W4410816491

Cites:

Cited by: 3

Related to: 10